Home - Plexus Ventures

Business Builders in Healthcare Pharma Medical Devices Biotech Consumer Health Healthcare

The Plexus Edge

Plexus’ clients come to us to discuss their strategic objectives and augment their capabilities to manage long and time-consuming transactions that would direct internal resources away from important activities. The following factors are what determines the Plexus’ advantage.

Network

We interact with key decision makers at healthcare companies of all sizes worldwide on a daily basis to discuss our broad portfolio of projects. We know them and they know Plexus.

Credibility

Companies react to Plexus’ projects as they trust the “reverse due diligence” we perform to assess the validity of a project.

Transaction Excellence

We bring structure into opportunistic and unstructured corporate and business development activities to achieve objectives quickly and with the best possible outcome offered by the market at a given time.

A Global Presence

Plexus industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.

LEARN MORE

By the Numbers

EU- Related Transactions Closed

Japan- Related Assigments Earned

US- Related Transactions Closed

Transactions Completed

Results

Divested Cinfa Biotech to Mundipharma

Sale of oncology biosimilar development company with late-stage product.

Divested J&J rights to OTC brands to Trimb Healthcare

Sale of a portfolio of antifungal OTC products.

Divested Novartis CH rights to Habitrol® to Dr. Reddy’s

FTC-mandated divestment of nicotine patch to complete big asset swap.

VIEW ALL

Our Clients

Plexus Ventures has worked with a wide range of clients across the Healthcare spectrum: pharma, consumer healthcare, biotech and
medtech companies as well as a variety of investor groups. These are some of our current partners.

LEARN MORE

News & Events

Plexus Ventures Assists Sanofi Consumer Health to Divest a Product Portfolio in Australia and South-East Asia to Phoenix Labs

Philadelphia, Pennsylvania, May 5, 2023 – Phoenix Labs (“Phoenix”) has acquired a portfolio of well-established consumer health products from Sanofi Consumer Health (“Sanofi”). The portfolio includes Proctosedyl™, the leading pharmacy-only haemorrhoid treatment in Australia and a number of Essential Remedies found in many Australian homes. Additionally, the divestment package includes the Proctosedyl™ business in China, Malaysia, New Zealand, Singapore, Taiwan, Thailand and Ireland, and Anthisan® in New Zealand

Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody

Philadelphia, Pennsylvania, February 17, 2023 – Plexus Ventures is pleased to announce the successful completion of an out-licensing project conducted on behalf of its client, Elthera AG of Switzerland.

Celon Pharma enters agreement with Zydus Lifesciences Ltd.

Philadelphia, Pennsylvania, December 2, 2022 – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Celon Pharma.